Journal article icon

Journal article

Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site

Abstract:

The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD and examine in vitro and in vivo effects of Nilotinib and Imatinib on endothelial cells to explain AOD-development. In contrast to Imatinib, Nilotinib was found to upregulate pro-atherogenic adhes...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1038/leu.2017.245

Authors


Hadzijusufovic, E More by this author
Albrecht-Schgoer, K More by this author
More by this author
Department:
Oxford, MSD, NDM, Target Discovery Institute
Hoermann, G More by this author
Grebien, F More by this author
Expand authors...
More from this funder
Grant:
F 4701-B20, F 4704-B20, F 5404-B20, and F 5412-B2
Publisher:
Springer Nature Publisher's website
Journal:
Leukemia Journal website
Volume:
31
Issue:
11
Pages:
2388–2397
Publication date:
2017-09-08
Acceptance date:
2017-07-17
DOI:
EISSN:
1476-5551
ISSN:
0887-6924
Pubs id:
pubs:710904
URN:
uri:39785be9-6ad0-4d2c-829e-248797f10938
UUID:
uuid:39785be9-6ad0-4d2c-829e-248797f10938
Local pid:
pubs:710904
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP